TY - JOUR
T1 - Novel therapeutic options in the inflammatory bowel disease world
AU - Noble, A.
AU - Baldassano, R.
AU - Mamula, P.
PY - 2008/1
Y1 - 2008/1
N2 - Advances in the understanding of the pathogenesis of inflammatory bowel disease have encouraged the development of many new therapies targeted at specific and non-specific mediators of the inflammatory bowel disease inflammatory pathway. The role of these therapies, including novel anti-tumour necrosis factor-α agents, anti-adhesion molecules, recombinant cytokines, myeloid growth factors, helminths, and probiotics, in the management of paediatric onset inflammatory bowel disease is promising and warrants further investigation.
AB - Advances in the understanding of the pathogenesis of inflammatory bowel disease have encouraged the development of many new therapies targeted at specific and non-specific mediators of the inflammatory bowel disease inflammatory pathway. The role of these therapies, including novel anti-tumour necrosis factor-α agents, anti-adhesion molecules, recombinant cytokines, myeloid growth factors, helminths, and probiotics, in the management of paediatric onset inflammatory bowel disease is promising and warrants further investigation.
UR - http://www.scopus.com/inward/record.url?scp=37049033316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37049033316&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2007.07.169
DO - 10.1016/j.dld.2007.07.169
M3 - Short survey
C2 - 17988966
AN - SCOPUS:37049033316
SN - 1590-8658
VL - 40
SP - 22
EP - 31
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 1
ER -